肝纤维化研究发展的问题  

Development of liver fibrosis research

作　　者：王晓柠[1] 刘平[1] 

机构地区：[1]上海中医药大学 上海高校中医内科学E-研究院肝肾疾病病证教育部重点实验室,201203

出　　处：《传染病信息》2012年第3期147-149,173,共4页Infectious Disease Information

基　　金：国家自然科学基金重大研究计划重点项目(90409020);上海市教育委员会创新团队资助项目(第1期);国家中医药管理局中医肝胆病重点学科项目;上海市教育委员会E-研究院建设计划项目(E03008)

摘　　要：抗肝纤维化是慢性肝病临床治疗方案中不可忽视的重要问题。研制疗效明确而又无明显不良反应的药物是国际上广泛关注的难点。中医药在抗肝纤维化研究中具有明显的优势和特色。建立严谨的临床设计及实施方案,开展大样本、多中心、随机盲法对照临床试验,是中医药抗肝纤维化研究最重要的问题。以肝脏活体组织检查和肝纤维化血清学指标进行综合评价,并进一步开展效应物质基础及作用机制的分析研究,是符合中医药自身特点的研究路径。Anti-fibrosis has been regarded as an important issue that can not be ignored in clinical treatment strategies for chronic liver disease. To develop the drugs with the reliable efficacy and without significant adverse reactions remains a puzzle attracting the international academic concern. Traditional Chinese medicine （TCM） has its own obvious advantages and characteristics in treating liver fibrosis. The most important issue in the study on anti-fibrosis with TCM is to develop the rigorous clinical research design and protocols, and to carry out a series of large sample size, multicenter, randomized, double-blind and controlled trials. Making comprehensive evaluation based on liver biopsy and serum biomarkers for diagnosing liver fibrosis, and further promoting the study on TCM material foundation and action mechanism, should be a research approach which conforms to the law of TCM development.

关 键 词：肝纤维化 中医药 临床试验 

分 类 号：R256.49[医药卫生—中医内科学]